Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae 0139 vaccine prototype
- 1 April 1995
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 345 (8955) , 949-952
- https://doi.org/10.1016/s0140-6736(95)90698-3
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- The Vibrio cholerae O139 serogroup antigen includes an O-antigen capsule and lipopolysaccharide virulence determinants.Proceedings of the National Academy of Sciences, 1994
- Cholera vaccines: fighting an ancient scourgeScience, 1994
- Emergence of a New Cholera Pandemic: Molecular Analysis of Virulence Determinants in Vibrio cholerae 0139 and Development of a Live Vaccine PrototypeThe Journal of Infectious Diseases, 1994
- Live bacterial vaccines: environmental aspectsCurrent Opinion in Biotechnology, 1994
- Vibrio cholerae 0139 specific gene sequencesThe Lancet, 1994
- O-Antigenic Lipopolysaccharide of Vibrio cholerae O139 Bengal, a New Epidemic Strain for Recent Cholera in the Indian SubcontinentBiochemical and Biophysical Research Communications, 1993
- Non-01 Vibrio choleraeThe Lancet, 1993
- CTX genetic element encodes a site-specific recombination system and an intestinal colonization factor.Proceedings of the National Academy of Sciences, 1993
- Emergence of novel strain of Vibrio cholerae with epidemic potential in southern and eastern IndiaThe Lancet, 1993
- Large outbreak of clinical cholera due to Vibrio cholerae non-01 in BangladeshThe Lancet, 1993